GB-4362
Various in combo with MMAE ADCs
PreclinicalIND study may proceed (Dec 2025)
Key Facts
Indication
Various in combo with MMAE ADCs
Phase
Preclinical
Status
IND study may proceed (Dec 2025)
Company
About Generate Biomedicines
Generate Biomedicines is a Flagship Pioneering company on a mission to program biology, using its proprietary Generate Platform to create novel protein therapeutics with unprecedented speed and precision. The company achieved a significant validation milestone with its IPO in March 2026, raising capital to advance a diversified pipeline led by GB-0895, a long-acting anti-TSLP antibody now in global Phase 3 studies for severe asthma. Its strategy leverages a continuous learning loop that integrates computational design with high-throughput experimental validation, aiming to build a broad portfolio of internally developed and partnered programs across immunology, oncology, and beyond.
View full company profile